Net interest expense for 2013 excludes approximately $12 million of non-cash interest expense related to the convertible senior notes due 2018 because we believe the exclusion facilitates investors' ability to understand the effect of our debt service obligations on our liquidity as well as comparison of Auxilium's operating results to those of our peer group companies.
See Table 5 attached for a summary of guidance.
See Table 6 for reconciliation of forecasted non-GAAP results to the most directly comparable GAAP measure.
Conference CallAuxilium will hold a conference call today, February 26, 2013 at 10:00 a.m. ET, to discuss fourth quarter and full year 2012 results, as well as the financial guidance it has provided for 2013. The presentation slides to be used during the call will be available on the "For Investors" section of the Company's web site under the "Presentations" tab at 10:00 a.m. E.T. A question and answer session will follow the presentation. The conference call and the presentation slides will be simultaneously web cast on the "For Investors" section of the Company's web site under the "Events" tab. The conference call will be archived for future review until May 26, 2013.Conference call details:Date:Tuesday, February 26, 2013Time:
10:00 a.m. ETDial-in (U.S.):866-510-0705Dial-in (International):617-597-5363Web cast:
http://www.auxilium.comPasscode:AUXILIUMTo access an audio replay of the call:Access number (U.S.):
888-286-8010 Access number (International):
617-801-6888Replay Passcode #:
92145279About AuxiliumAuxilium is a specialty biopharmaceutical company with a focus on developing an
|SOURCE Auxilium Pharmaceuticals, Inc.|
Copyright©2012 PR Newswire.
All rights reserved